Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-02
What Is Retatrutide? Benefits, Research & Safety
An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.
Also known as:
LY3437943
Triple G
GGG agonist
Educational Content Only: This page provides research-based information for educational purposes. Retatrutide is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
GLP-1 Agonists
Half-Life
Approximately 6 days (estimated from Phase 2 data)
UK Status
NOT APPROVED. Investigational compound. May be available only through clinical trial participation.
EU Status
NOT APPROVED. Investigational compound in Phase 3 clinical trials.
Overview
Retatrutide represents the cutting edge of incretin-based metabolic therapy, being a first-in-class triple agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Developed by Eli Lilly, it has shown unprecedented efficacy in Phase 2 clinical trials.
While dual agonists like tirzepatide activated two receptors, retatrutide adds glucagon receptor activation—initially counterintuitive since glucagon raises blood sugar. However, glucagon also increases energy expenditure, promotes fat oxidation, and may reduce appetite independently of GLP-1.
In the Phase 2 trial, retatrutide produced mean weight loss of 24.2% at the highest dose—exceeding all previous pharmaceutical interventions and rivalling outcomes of bariatric surgery. Approximately 26% of participants lost more than 30% of their body weight.
**Critical Note:** Retatrutide is NOT approved for any use. It remains an investigational compound in clinical trials. Information here is for educational purposes about ongoing research. It should NOT be purchased from unregulated sources.
Discovery & History
Retatrutide's development builds on the success of tirzepatide and the scientific insight that glucagon, despite raising blood sugar, has metabolically beneficial effects that could be harnessed in combination with incretins.
**Scientific Rationale:**
**Glucagon's Dual Nature:**
- Traditionally viewed negatively in diabetes (raises blood sugar)
- However, glucagon also increases energy expenditure
- Promotes hepatic fat oxidation
- May suppress appetite independently
- Combined with GLP-1, the glucose-raising effect can be offset
**Development Timeline:**
• **2018:** Eli Lilly begins development of triple agonist compounds
• **2019:** LY3437943 (retatrutide) enters Phase 1 trials
• **2022:** Phase 2 trial results presented showing unprecedented weight loss
• **2023:** Phase 2 results published in New England Journal of Medicine
• **2023-2024:** Phase 3 trials (TRIUMPH program) initiated
• **2025-2026:** Phase 3 trials ongoing; regulatory submission anticipated
**The Triple Agonist Concept:**
Retatrutide was designed to combine:
- GLP-1 effects: Appetite suppression, insulin secretion, glucose control
- GIP effects: Enhanced insulin response, central appetite effects
- Glucagon effects: Increased energy expenditure, fat oxidation
The challenge was balancing these effects to maximise weight loss while maintaining glucose control—which the Phase 2 data suggests has been achieved.
Mechanism of Action
Retatrutide simultaneously activates three metabolic receptors, creating a comprehensive approach to energy balance:
**GLP-1 Receptor Activation:**
- Reduces appetite through hypothalamic signalling
- Enhances glucose-dependent insulin secretion
- Slows gastric emptying
- Suppresses inappropriate glucagon secretion
- Provides established metabolic benefits seen with semaglutide/tirzepatide
**GIP Receptor Activation:**
- Synergistic appetite suppression with GLP-1
- Enhanced insulin secretion
- Potential direct effects on adipose tissue
- Contributes to superior efficacy of dual/triple agonists
**Glucagon Receptor Activation (The Novel Component):**
This is what distinguishes retatrutide from tirzepatide:
• **Increased Energy Expenditure:** Glucagon increases thermogenesis and basal metabolic rate, meaning more calories burned at rest.
• **Enhanced Fat Oxidation:** Glucagon promotes breakdown of fat stores in the liver and adipose tissue for use as fuel.
• **Hepatic Effects:** May improve fatty liver by promoting hepatic fat oxidation—potentially significant for NAFLD/NASH.
• **Appetite Regulation:** Glucagon may have independent appetite-suppressing effects in the brain.
• **Glucose Balance:** While glucagon raises blood sugar, the GLP-1 and GIP components provide sufficient insulin enhancement and glucagon suppression to maintain glucose control.
**Net Effect:**
The triple mechanism creates a metabolic state favouring weight loss from multiple angles:
- Reduced energy intake (appetite suppression from GLP-1, GIP, glucagon)
- Increased energy expenditure (glucagon's thermogenic effect)
- Enhanced fat utilisation (glucagon's lipolytic effect)
- Maintained glucose control (GLP-1/GIP insulin effects offset glucagon)
[Diagram Placeholder: Triple receptor signalling pathways showing GLP-1, GIP, and glucagon receptor activation with effects on pancreas, liver, adipose tissue, and central nervous system]
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Weight loss of 24.2% at highest dose in Phase 2—potentially the most effective pharmaceutical weight loss
- 226% of participants achieved ≥30% weight loss (matching surgical outcomes)
- 3Significant reductions in liver fat (up to 86% reduction in hepatic steatosis)
- 4Substantial improvements in glycaemic control in participants with diabetes
- 5Marked reductions in waist circumference
- 6Improvements in blood pressure and lipid profiles
- 7High proportion achieving metabolically healthy weight status
- 8Potential disease-modifying effects on NAFLD/NASH
- 9Maintained glucose control despite glucagon agonism
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Phase 2 studied doses up to 12mg weekly; exact dosing for approval TBD |
| Frequency | Once weekly subcutaneous injection (in trials) |
| Duration | Phase 2 was 48 weeks; long-term data awaited from Phase 3 |
| Notes | ⚠️ RETATRUTIDE IS NOT APPROVED FOR ANY USE. It is an investigational compound in Phase 3 clinical trials. The information above is from research publications and does not represent prescribing guidance. Do NOT attempt to obtain retatrutide from unregulated sources. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (investigational—once weekly in trials)
| Half-Life | Stability |
|---|---|
| Approximately 6 days (estimated from Phase 2 data) | Not applicable—investigational compound not commercially available |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (most common, similar to other incretin therapies)
- Diarrhoea
- Vomiting
- Constipation
- Decreased appetite
- Dyspepsia
- Abdominal pain
- Injection site reactions
Rare Risks & Concerns
- Pancreatitis (theoretical risk with all incretin therapies)
- Gallbladder disease (accelerated by rapid weight loss)
- Thyroid C-cell tumours (theoretical—class warning)
- Unknown long-term risks (limited Phase 2 data)
- Potential cardiovascular effects (being evaluated in trials)
- Unknown effects of chronic glucagon receptor activation
Contraindications
- This is an INVESTIGATIONAL compound—not approved for any use
- Should only be used within clinical trial settings
- Presumed contraindications similar to GLP-1 agonists:
- - Personal/family history of medullary thyroid carcinoma
- - Multiple Endocrine Neoplasia syndrome type 2
- - Pregnancy and breastfeeding
- - Type 1 diabetes
- - History of pancreatitis
UK & EU Regulatory Context
🇬🇧 United Kingdom
NOT APPROVED. Investigational compound. May be available only through clinical trial participation.
🇪🇺 European Union
NOT APPROVED. Investigational compound in Phase 3 clinical trials.
⚠️ IMPORTANT: Retatrutide is NOT approved by any regulatory authority for any indication. It is currently in Phase 3 clinical trials. Any products sold online claiming to be retatrutide are likely counterfeit, unverified, and potentially dangerous. Do not purchase from unregulated sources.
Clinical Studies Summary
Phase 2 Retatrutide Trial
Landmark Phase 2 study showing dose-dependent weight loss up to 24.2% at 12mg dose over 48 weeks. 26% of participants lost ≥30% body weight. Gastrointestinal side effects were common but manageable.
N Engl J Med. 2023;389:514-526View on PubMed
Retatrutide Effects on Hepatic Steatosis
Substudy showing retatrutide reduced liver fat by up to 86% from baseline, with 93% of participants achieving resolution of hepatic steatosis at the highest dose.
N Engl J Med. 2023 (substudy data)View on PubMed
TRIUMPH Phase 3 Program
Ongoing Phase 3 trials evaluating retatrutide for obesity and type 2 diabetes. Results expected 2025-2026. Includes cardiovascular outcomes and metabolic endpoint trials.
ClinicalTrials.gov (multiple trials)View on PubMed
Looking for Retatrutide?
Source research-grade Retatrutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreGLP-1
A natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.
Learn moreSemaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn more